- Home
- EDSA vs ATHA Comparison
EDSA vs ATHA Comparison
Compare EDSA & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- ATHA
- Stock Information
- Founded
- EDSA 2015
- ATHA 2011
- Country
- EDSA Canada
- ATHA United States
- Employees
- EDSA N/A
- ATHA N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- EDSA Health Care
- ATHA Health Care
- Exchange
- EDSA Nasdaq
- ATHA Nasdaq
- Market Cap
- EDSA 17.2M
- ATHA 14.8M
- IPO Year
- EDSA N/A
- ATHA 2020
- Fundamental
- Price
- EDSA $2.39
- ATHA $0.38
- Analyst Decision
- EDSA Strong Buy
- ATHA Hold
- Analyst Count
- EDSA 2
- ATHA 1
- Target Price
- EDSA $13.00
- ATHA $0.50
- AVG Volume (30 Days)
- EDSA 11.7K
- ATHA 177.7K
- Earning Date
- EDSA 08-08-2025
- ATHA 11-06-2025
- Dividend Yield
- EDSA N/A
- ATHA N/A
- EPS Growth
- EDSA N/A
- ATHA N/A
- EPS
- EDSA N/A
- ATHA N/A
- Revenue
- EDSA N/A
- ATHA N/A
- Revenue This Year
- EDSA N/A
- ATHA N/A
- Revenue Next Year
- EDSA N/A
- ATHA N/A
- P/E Ratio
- EDSA N/A
- ATHA N/A
- Revenue Growth
- EDSA N/A
- ATHA N/A
- 52 Week Low
- EDSA $1.55
- ATHA $0.22
- 52 Week High
- EDSA $5.00
- ATHA $0.83
- Technical
- Relative Strength Index (RSI)
- EDSA 51.55
- ATHA 46.23
- Support Level
- EDSA $2.41
- ATHA $0.35
- Resistance Level
- EDSA $2.47
- ATHA $0.39
- Average True Range (ATR)
- EDSA 0.09
- ATHA 0.02
- MACD
- EDSA -0.01
- ATHA -0.00
- Stochastic Oscillator
- EDSA 48.15
- ATHA 50.00
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.